We are live on ! Find out more
BLFS icon

BioLife Solutions

164 hedge funds and large institutions have $1B invested in BioLife Solutions in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 56 increasing their positions, 49 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,876% more call options, than puts

Call options by funds: $336K | Put options by funds: $17K

114% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 14

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

22% more capital invested

Capital invested by funds: $823M → $1B (+$177M)

14% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 49

10% more funds holding

Funds holding: 149164 (+15)

3.39% more ownership

Funds ownership: 98.03%101.42% (+3.4%)

Holders
164
Holders Change
+15
Holders Change %
+10.07%
% of All Funds
2.37%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
30
Increased
56
Reduced
49
Closed
14
Calls
$336K
Puts
$17K
Net Calls
+$319K
Net Calls Change
-$3.26M
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1
Casdin Capital
New York
$187M
BlackRock
2
BlackRock
New York
$118M +$488K +25,130 +0.5%
Invesco
3
Invesco
Georgia
$71.2M +$39.7M +2,044,714 +160%
Vanguard Group
4
Vanguard Group
Pennsylvania
$59.7M -$1.59M -81,871 -3%
FAM
5
Fred Alger Management
New York
$33.8M +$1.72M +88,840 +6%
William Blair Investment Management
6
William Blair Investment Management
Illinois
$33.7M -$3.01M -155,142 -9%
State Street
7
State Street
Massachusetts
$28.2M +$342K +17,634 +1%
CRM
8
Cramer Rosenthal McGlynn
Connecticut
$27.9M +$2.59M +133,601 +11%
PCM
9
Palisade Capital Management
New Jersey
$26.4M -$384K -19,790 -2%
Ameriprise
10
Ameriprise
Minnesota
$23.7M -$120K -6,178 -0.6%
Millennium Management
11
Millennium Management
New York
$21.6M -$15.6M -803,853 -44%
PCM
12
Portolan Capital Management
Massachusetts
$21.5M +$2.58M +132,691 +15%
GIM
13
Granahan Investment Management
Massachusetts
$20.3M -$2.61M -134,321 -12%
RA
14
Royce & Associates
New York
$19.6M +$7.71M +397,445 +77%
GCM
15
Geneva Capital Management
Wisconsin
$18.5M -$309K -15,914 -2%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$17.7M +$701K +36,108 +5%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$17M +$1.29M +66,422 +9%
GS
18
Gagnon Securities
New York
$12.4M -$314K -16,159 -3%
Bank of America
19
Bank of America
North Carolina
$11.7M +$928K +47,832 +10%
VOYA Investment Management
20
VOYA Investment Management
Georgia
$10.3M +$9.13M +470,338 +4,079%
SIMG
21
Stephens Investment Management Group
Texas
$9.24M -$382K -19,666 -4%
CRC
22
Curi RMB Capital
Illinois
$8.99M -$30.6K -1,576 -0.4%
MOACM
23
Mutual of America Capital Management
New York
$8.59M +$7.78M +400,916 New
MIM
24
Meros Investment Management
Texas
$8.57M +$128K +6,586 +2%
RIM
25
Ranger Investment Management
Texas
$8.24M +$140K +7,234 +2%

BLFS Hedge Fund Activity: Q2 2024 in Review

164 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q2 2024, worth a combined $1B — up 22% from $823M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new BLFS positions and 14 closed out — a net gain of 16 holders — while 56 added to existing stakes and 49 trimmed.

The largest buyer was Invesco, adding an estimated $39.7M. The largest seller was Millennium Management, cutting an estimated $15.6M.

  • 164 institutional investors held BioLife Solutions (BLFS) as of Q2 2024, up from 149 in Q1 2024.
  • Funds reported $1B of BioLife Solutions stock for Q2 2024, up 22% quarter-over-quarter.
  • 30 funds opened new BioLife Solutions positions in Q2 2024 and 14 closed out, a net change of +16 holders.
  • The largest BioLife Solutions buyer in Q2 2024 was Invesco, an estimated $39.7M added.
  • The largest BioLife Solutions seller in Q2 2024 was Millennium Management, an estimated $15.6M sold.

Based on aggregated 13F filings for Q2 2024.